Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Franchini Website

Genoveffa Franchini, M.D.

Selected Publications

1)  Berzofsky JA, Franchini G.
Human/Simian immunodeficiency virus transmission and infection at mucosal sites. In: Mucosal Immunology.
Elsevier; 2014. In Press. [Book Chapter]
2)  Pise-Masison C, Amarante MF, Enose-Akahata Y, Buchmann RC, Fenizia C, Washington Parks R, Edwards D, Fiocchi M, Alcantara LC, Bialuk I, Graham J, Walser J, McKinnon K, Galvao-Castro B, Gessain A, Venzon D, Jacobson S, Franchini G.
Co-dependence of HTLV-1 p12 and p8 Functions in Virus Persistence.
PLOS Pathogens. 2014.
In Press. [Journal]
3)  Gupta S, Pegu P, Venzon DJ, Gach JS, Ma Z, Landucci G, Miller CJ, Franchini G, Forthal DN.
Enhanced In Vitro Transcytosis of Simian Immunodeficiency Virus Mediated by Vaccine-Induced Antibody Predicts Transmitted/Founder Strain Number After Rectal Challenge.
J. Infect. Dis. 2014.
In Press. [Journal]
4)  Moniuszko M, Liyanage NP, Doster MN, Parks RW, Grubczak K, Lipinska D, McKinnon K, Brown C, Hirsch V, Vaccari M, Gordon S, Pegu P, Fenizia C, Flisiak R, Grzeszczuk A, Dabrowska M, Robert-Guroff M, Silvestri G, Stevenson M, McCune J, Franchini G.
Glucocorticoid Treatment at Moderate Doses of SIVmac251-Infected Rhesus Macaques Decreases the Frequency of Circulating CD14(+)CD16(++) Monocytes But Does Not Alter the Tissue Virus Reservoir.
AIDS Res. Hum. Retroviruses. 2014.
In Press. [Journal]
5)  Vargas-Inchaustegui DA, Tuero I, Mohanram V, Musich T, Pegu P, Valentin A, Sui Y, Rosati M, Bear J, Venzon DJ, Kulkarni V, Alicea C, Pilkington GR, Liyanage NP, Demberg T, Gordon SN, Wang Y, Hogg AE, Frey B, Patterson LJ, DiPasquale J, Montefiori DC, Sardesai NY, Reed SG, Berzofsky JA, Franchini G, Felber BK, Pavlakis GN, Robert-Guroff M.
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.
Clin. Immunol. 153: 308-322, 2014.
In Press. [Journal]
6)  Liyanage NP, Gordon SN, Doster MN, Pegu P, Vaccari M, Shukur N, Schifanella L, Pise-Masison CA, Lipinska D, Grubczak K, Moniuszko M, Franchini G.
Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac251 infection of macaques.
Virology. 450-451: 359-68, 2014.
7)  Fenizia C, Fiocchi M, Jones K, Parks RW, Ceribelli M, Chevalier SA, Edwards D, Ruscetti F, Pise-Masison CA, Franchini G.
Human T-cell leukemia/lymphoma virus type 1 p30, but not p12/p8, counteracts toll-like receptor 3 (TLR3) and TLR4 signaling in human monocytes and dendritic cells.
J. Virol. 88: 393-402, 2014.
8)  Edwards D, Fukumoto R, de Castro-Amarante MF, Alcantara LC, Galvão-Castro B, Washington Parks R, Pise-Masison C, Franchini G.
Palmitoylation and p8-mediated human T-cell leukemia virus type 1 transmission.
J. Virol. 88: 2319-22, 2014.
9)  Teigler JE, Phogat S, Franchini G, Hirsch VM, Michael NL, Barouch DH.
The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.
J. Virol. 88: 1809-14, 2014.
10)  Vaccari M, Fenizia C, Ma Z, Hryniewicz A, Boasso A, Doster MN, Miller CJ, Lindegardh N, Tarning J, Landay AL, Shearer GM, Franchini G.
Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques.
AIDS Res. Hum. Retroviruses. 30: 355-62, 2014.
11)  Sui Y, Hogg A, Wang Y, Frey B, Yu H, Xia Z, Venzon D, McKinnon K, Smedley J, Gathuka M, Klinman D, Keele BF, Langermann S, Liu L, Franchini G, Berzofsky JA.
Vaccine-induced myeloid cell population dampens protective immunity to SIV.
J. Clin. Invest. 124: 2538-49, 2014.
12)  Vaccari M, Halwani R, Patterson LJ, Boasso A, Beal J, Tryniszewska E, Hryniewicz A, Venzon D, Haddad EK, El-Far M, Rosati M, Pavlakis GN, Felber BK, Al-Muhsen S, Robert-Guroff M, Sekaly R, Franchini G.
Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS.
J. Virol. 87: 3526-37, 2013.
13)  Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, Ferrari G, Pal R, Ferrari MG, Whitney S, Hudacik L, Billings E, Rao M, Montefiori D, Tomaras G, Alam SM, Fenizia C, Lifson JD, Stablein D, Tartaglia J, Michael N, Kim J, Venzon D, Franchini G.
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.
J. Virol. 87: 1708-19, 2013.
14)  Strbo N, Vaccari M, Pahwa S, Kolber MA, Doster MN, Fisher E, Gonzalez L, Stablein D, Franchini G, Podack ER.
Cutting Edge: Novel Vaccination Modality Provides Significant Protection against Mucosal Infection by Highly Pathogenic Simian Immunodeficiency Virus.
J. Immunol. 190: 2495-9, 2013.
15)  Mendoza D, Migueles SA, Rood JE, Peterson B, Johnson S, Doria-Rose N, Schneider D, Rakasz E, Trivett MT, Trubey CM, Coalter V, Hallahan CW, Watkins D, Franchini G, Lifson JD, Connors M.
Cytotoxic Capacity of SIV-Specific CD8(+) T Cells against Primary Autologous Targets Correlates with Immune Control in SIV-Infected Rhesus Macaques.
PLoS Pathog. 9: e1003195, 2013.
16)  Sui Y, Gordon S, Franchini G, Berzofsky JA.
Nonhuman primate models for HIV/AIDS vaccine development.
Curr Protoc Immunol. 102: Unit 12.14., 2013.
17)  Dunham RM, Gordon SN, Vaccari M, Piatak M, Huang Y, Deeks SG, Lifson J, Franchini G, McCune JM.
Preclinical evaluation of HIV eradication strategies in the simian immunodeficiency virus-infected rhesus macaque: a pilot study testing inhibition of indoleamine 2,3-dioxygenase.
AIDS Res. Hum. Retroviruses. 29: 207-14, 2013.
18)  Vaccari M, Keele BF, Bosinger SE, Doster MN, Ma Z, Pollara J, Hryniewicz A, Ferrari G, Guan Y, Forthal DN, Venzon D, Fenizia C, Morgan T, Montefiori D, Lifson JD, Miller CJ, Silvestri G, Rosati M, Felber BK, Pavlakis GN, Tartaglia J, Franchini G.
Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.
J. Virol. 87: 3538-48, 2013.
19)  Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M.
Superior T memory stem cell persistence supports long-lived T cell memory.
J. Clin. Invest. 123: 594-9, 2013.
20)  Vaccari M, Boasso A, Fenizia C, Fuchs D, Hryniewicz A, Morgan T, Weiss D, Doster MN, Heraud JM, Shearer GM, Franchini G.
Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2',3'-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade.
J. Virol. 86: 108-13, 2012.
21)  Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C, Hidajat R, Brocca-Cofano E, Cuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G.
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.
J. Immunol. 188: 714-23, 2012.
22)  Strbo N, Vaccari M, Pahwa S, Kolber MA, Fisher E, Gonzalez L, Doster MN, Hryniewicz A, Felber BK, Pavlakis GN, Franchini G, Podack ER.
Gp96 SIV Ig immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa.
Vaccine. 29: 2619-25, 2011.
23)  Pallikkuth S, Rogers K, Villinger F, Dosterii M, Vaccari M, Franchini G, Pahwa R, Pahwa S.
Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication.
Vaccine. 29: 9229-38, 2011.
24)  Tosi G, Forlani G, Andresen V, Turci M, Bertazzoni U, Franchini G, Poli G, Accolla RS.
Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.
J. Virol. 85: 10719-29, 2011.
25)  Edwards D, Fenizia C, Gold H, de Castro-Amarante MF, Buchmann C, Pise-Masison CA, Franchini G.
Orf-I and orf-II-encoded proteins in HTLV-1 infection and persistence.
Viruses. 3: 861-85, 2011.
26)  Gordon SN, Cecchinato V, Andresen V, Heraud JM, Hryniewicz A, Parks RW, Venzon D, Chung HK, Karpova T, McNally J, Silvera P, Reimann KA, Matsui H, Kanehara T, Shinmura Y, Yokote H, Franchini G.
Smallpox vaccine safety is dependent on T cells and not B cells.
J. Infect. Dis. 203: 1043-53, 2011.
27)  Andresen V, Pise-Masison CA, Sinha-Datta U, Bellon M, Valeri V, Washington Parks R, Cecchinato V, Fukumoto R, Nicot C, Franchini G.
Suppression of HTLV-1 replication by Tax-mediated re-routing of the p13 viral protein to nuclear speckles.
Blood. 2011.
28)  Sui Y, Gagnon S, Dzutsev A, Zhu Q, Yu H, Hogg A, Wang Y, Xia Z, Belyakov IM, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Berzofsky JA.
TLR agonists and/or IL-15 adjuvanted mucosal SIV vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques.
Vaccine. 30: 59-68, 2011.
29)  Fenizia C, Keele BF, Nichols D, Cornara S, Binello N, Vaccari M, Pegu P, Robert-Guroff M, Ma ZM, Miller CJ, Venzon D, Hirsch V, Franchini G.
TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure.
J. Virol. 85: 12399-409, 2011.
30)  Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal DN, Franchini G.
Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.
Vaccine. 30: 78-94, 2011.
31)  Van Prooyen N, Andresen V, Gold H, Bialuk I, Pise-Masison C, Franchini G.
Hijacking the T-cell communication network by the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) p12 and p8 proteins.
Molecular aspects of medicine. 2010.
32)  Franchini G.
HTLV-1 and HIV-1.
Molecular aspects of medicine. 2010.
33)  Silic-Benussi M, Biasiotto R, Andresen V, Franchini G, D'Agostino DM, Ciminale V.
HTLV-1 p13, a small protein with a busy agenda.
Molecular aspects of medicine. 2010.
34)  Van Prooyen N, Gold H, Andresen V, Schwartz O, Jones K, Ruscetti F, Lockett S, Gudla P, Venzon D, Franchini G.
Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission.
Proc. Natl. Acad. Sci. U.S.A. 107: 20738-43, 2010.
35)  Sui Y, Zhu Q, Gagnon S, Dzutsev A, Terabe M, Vaccari M, Venzon D, Klinman D, Strober W, Kelsall B, Franchini G, Belyakov IM, Berzofsky JA.
Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques.
Proc. Natl. Acad. Sci. U.S.A. 107: 9843-8, 2010.
36)  Vaccari M, Franchini G.
Memory T cells in Rhesus macaques.
Adv. Exp. Med. Biol. 684: 126-44, 2010.
37)  Vaccari M, Poonam P, Franchini G.
Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.
Expert Rev Vaccines. 9: 997-1005, 2010.
38)  Gordon SN, Weissman AR, Cecchinato V, Fenizia C, Ma ZM, Lee TH, Zaffiri L, Andresen V, Parks RW, Jones KS, Heraud JM, Ferrari MG, Chung HK, Venzon D, Mahieux R, Murphy EL, Jacobson S, Miller CJ, Ruscetti FW, Franchini G.
Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques.
J. Virol. 84: 3043-58, 2010.
39)  Valeri VW, Hryniewicz A, Andresen V, Jones K, Fenizia C, Bialuk I, Chung HK, Fukumoto R, Washington Parks R, Ferrari MG, Nicot C, Cecchinato V, Ruscetti F, Franchini G.
Requirement of the human T-cell leukemia virus p12 and p30 genes for infectivity of human dendritic cells and macaques but not rabbits.
Blood. 2010.
40)  Cecchinato V, Franchini G.
Th17 cells in pathogenic simian immunodeficiency virus infection of macaques.
Curr Opin HIV AIDS. 5: 141-5, 2010.
41)  Moutaftsi M, Tscharke DC, Vaughan K, Koelle DM, Stern L, Calvo-Calle M, Ennis F, Terajima M, Sutter G, Crotty S, Drexler I, Franchini G, Yewdell JW, Head SR, Blum J, Peters B, Sette A.
Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.
Future Microbiol. 5: 221-39, 2010.
42)  Poirier MC, Olivero OA, Hardy AW, Franchini G, Borojerdi JP, Walker VE, Walker DM, Shearer GM.
Antiretroviral activity of the aminothiol WR1065 against Human Immunodeficiency virus (HIV-1) in vitro and Simian Immunodeficiency virus (SIV) ex vivo.
AIDS research and therapy. 6: 24, 2009.
43)  Franchini G.
Choosing the right memory T cell for HIV.
Nat. Med. 15: 244-6, 2009.
44)  Boasso A, Vaccari M, Fuchs D, Hardy AW, Tsai WP, Tryniszewska E, Shearer GM, Franchini G.
Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques.
J. Immunol. 182: 4313-20, 2009.
45)  Herbeuval JP, Nilsson J, Boasso A, Hardy AW, Vaccari M, Cecchinato V, Valeri V, Franchini G, Andersson J, Shearer GM.
HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques.
AIDS. 23: 35-40, 2009.
46)  Moreno-Fernandez ME, Zapata W, Blackard JT, Franchini G, Chougnet CA.
Human regulatory T cells are targets for human immunodeficiency Virus (HIV) infection, and their susceptibility differs depending on the HIV type 1 strain.
J. Virol. 83: 12925-33, 2009.
47)  Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D.
Unsung hero Robert C. Gallo.
Science. 323: 206-7, 2009.
48)  Cecchinato V, Trindade CJ, Laurence A, Heraud JM, Brenchley JM, Ferrari MG, Zaffiri L, Tryniszewska E, Tsai WP, Vaccari M, Parks RW, Venzon D, Douek DC, O'Shea JJ, Franchini G.
Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques.
Mucosal immunology. 1: 279-88, 2008.
49)  Vaccari M, Boasso A, Ma ZM, Cecchinato V, Venzon D, Doster MN, Tsai WP, Shearer GM, Fuchs D, Felber BK, Pavlakis GN, Miller CJ, Franchini G.
CD4+ T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection.
Mucosal immunology. 1: 497-507, 2008.
50)  Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.
Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
J. Virol. 82: 6829-37, 2008.
51)  Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai WP, Petrovas C, Fuchs D, Heraud JM, Venzon D, Shearer GM, Koup RA, Lowy I, Miller CJ, Franchini G.
Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection.
J. Immunol. 180: 5439-47, 2008.
52)  Fukumoto R, Andresen V, Bialuk I, Cecchinato V, Walser JC, Valeri VW, Nauroth JM, Gessain A, Nicot C, Franchini G.
In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein.
Blood. 2008.
53)  Vaccari M, Mattapallil J, Song K, Tsai W, Hryniewicz A, Venzon D, Zanetti M, Reimann KA, Roederer M, Franchini G.
Reduced Protection From SIVmac251 Afforded by Memory CD8+ T-cells Induced by Vaccination in Condition of CD4+ T-cell Deficiency.
J. Virol. Epub ahead of print, 2008.
54)  Fukumoto R, Dundr M, Nicot C, Adams A, Valeri VW, Samelson LE, Franchini G.
Inhibition of TCR Signal Transduction and Viral Expression by the Linker for Activation of T Cells-Interacting p12I Protein of HTLV-1.
J Virol. 81: 9088-99, 2007.
55)  Hryniewicz A, Price DA, Moniuszko M, Boasso A, Edghill-Spano Y, West SM, Venzon D, Vaccari M, Tsai WP, Tryniszewska E, Nacsa J, Villinger F, Ansari AA, Trindade CJ, Morre M, Brooks D, Arlen P, Brown HJ, Kitchen CM, Zack JA, Douek DC, Shearer GM, Lewis MG, Koup RA, Franchini G.
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virusmac251-infected macaques.
J. Immunol. 178: 3492-504, 2007.
56)  von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK.
Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.
J. Virol. 81: 1972-9, 2007.
57)  Boasso A, Vaccari M, Hryniewicz A, Fuchs D, Nacsa J, Cecchinato V, Andersson J, Franchini G, Shearer GM, Chougnet C.
Regulatory T cell markers, indoleamine (2,3)-dioxygenase and virus levels in spleen and gut during progressive SIV infection.
J Virol. 81: 11593-603, 2007.
58)  Petrovas C, Price DA, Mattapallil J, Ambrozak DR, Geldmacher C, Cecchinato V, Vaccari M, Tryniszewska E, Gostick E, Roederer M, Douek DC, Morgan SH, Davis SJ, Franchini G, Koup RA.
SIV-specific CD8+T-cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection.
Blood. 110: 928-36, 2007.
59)  Tryniszewska E, Kaczmarski M, Colombini-Hatch S, Franchini G.
[Detection of human herpesvirus type 8 (HHV-8) in the central nervous system in patients from Poland].
Przegl Epidemiol. 60 Suppl 1: 166, 2006.
60)  Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai W, Heraud J, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G.
CTLA-4 blockade decreases TGF-{beta}, indoleamine 2,3- dioxygenase, and viral RNA expression in tissues of SIVmac251-infected macaques.
Blood. 108: 3834-42, 2006.
61)  Moniuszko M, Edghill-Smith Y, Venzon D, Stevceva L, Nacsa J, Tryniszewska E, Tsai WP, Franchini G.
Decreased number of CD4+ and CD8+ T cells that express the interleukin-7 receptor in blood and tissues of SIV-infected macaques.
Virology. 356: 188-97, 2006.
62)  Boasso A, Vaccari M, Nilsson J, Shearer GM, Andersson J, Cecchinato V, Chougnet C, Franchini G.
Do regulatory T-cells play a role in AIDS pathogenesis?.
AIDS Rev. 8: 141-7, 2006.
63)  Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, Shearer GM, Andersson J, Chougnet C.
HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS.
Blood. 108: 3808-17, 2006.
64)  Ghorbel S, Sinha-Datta U, Dundr M, Brown M, Franchini G, Nicot C.
Human T-cell leukemia virus type I p30 nuclear/nucleolar retention is mediated through interactions with RNA and a constituent of the 60 S ribosomal subunit.
J. Biol. Chem. 281: 37150-8, 2006.
65)  Belyakov IM, Kuznetsov VA, Kelsall B, Klinman D, Moniuszko M, Lemon M, Markham PD, Pal R, Clements JD, Lewis MG, Strober W, Franchini G, Berzofsky JA.
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.
Blood. 107: 3258-64, 2006.
66)  Hel Z, Tsai WP, Tryniszewska E, Nacsa J, Markham PD, Lewis MG, Pavlakis GN, Felber BK, Tartaglia J, Franchini G.
Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes.
J Immunol. 176: 85-96, 2006.
67)  Heraud JM, Edghill-Smith Y, Ayala V, Kalisz I, Parrino J, Kalyanaraman VS, Manischewitz J, King LR, Hryniewicz A, Trindade CJ, Hassett M, Tsai WP, Venzon D, Nalca A, Vaccari M, Silvera P, Bray M, Graham BS, Golding H, Hooper JW, Franchini G.
Subunit Recombinant Vaccine Protects against Monkeypox.
J. Immunol. 177: 2552-64, 2006.
68)  Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, Hocker L, Hudacik L, Rose N, Nacsa J, Edghill-Smith Y, Moniuszko M, Hel Z, Belyakov IM, Berzofsky JA, Parks RW, Markham PD, Letvin NL, Tartaglia J, Franchini G.
Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIVKU2 RNA Levels.
J Virol. 80: 3732-42, 2006.
69)  Zanetti M, Franchini G.
T cell memory and protective immunity by vaccination: is more better?.
Trends Immunol. 27: 511-7, 2006.
70)  Van Rompay KK, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, Earl P, Harvey D, Franchini G, Tartaglia J, Montefiori D, Hattangadi S, Moss B, Marthas ML.
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV.
J. Acquir. Immune Defic. Syndr. 38: 124-34, 2005.
71)  Nacsa J, Edghill-Smith Y, Tsai WP, Venzon D, Tryniszewska E, Hryniewicz A, Moniuszko M, Kinter A, Smith KA, Franchini G.
Contrasting Effects of Low-Dose IL-2 on Vaccine-Boosted Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cells in Macaques Chronically Infected with SIVmac251.
J Immunol. 174: 1913-21, 2005.
72)  Moniuszko M, Bogdan D, Pal R, Venzon D, Stevceva L, Nacsa J, Tryniszewska E, Edghill-Smith Y, Wolinsky SM, Franchini G.
Correlation between viral RNA levels but not immune responses in plasma and tissues of macaques with long-standing SIVmac251 infection.
Virology. 333: 159-68, 2005.
73)  Nicot C, Harrod RL, Ciminale V, Franchini G.
Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions.
Oncogene. 24: 6026-34, 2005.
74)  Murphy E, Jacobson S, Franchini G, Taylor GP, Hanchard B, Morgan O, Lairmore M.
International Retrovirology Association brings together scientists and clinicians to bridge discoveries about human T-lymphotropic viruses from the laboratory to clinical trials.
Retrovirology. 2: 22, 2005.
75)  Edghill-Smith Y, Bray M, Whitehouse CA, Miller D, Mucker E, Manischewitz J, King LR, Robert-Guroff M, Hryniewicz A, Venzon D, Meseda C, Weir J, Nalca A, Livingston V, Wells J, Lewis MG, Huggins J, Zwiers SH, Golding H, Franchini G.
Smallpox Vaccine Does Not Protect Macaqueswith AIDS from a Lethal MonkeypoxVirus Challenge.
J Infect Dis. 191: 372-81, 2005.
76)  Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, Bray M, Nalca A, Hooper JW, Whitehouse CA, Schmitz JE, Reimann KA, Franchini G.
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus.
Nat Med. 11: 740-7, 2005.
77)  Vaccari M, Trindade CJ, Venzon D, Zanetti M, Franchini G.
Vaccine-Induced CD8+ Central Memory T Cells in Protection from Simian AIDS.
J Immunol. 175: 3502-7, 2005.
78)  Nacsa J, Radaelli A, Edghill-Smith Y, Venzon D, Tsai WP, Morghen Cde G, Panicali D, Tartaglia J, Franchini G.
Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.
Vaccine. 22: 597-606, 2004.
79)  Stevceva L, Moniuszko M, Alvarez X, Lackner AA, Franchini G.
Functional simian immunodeficiency virus Gag-specific CD8+ intraepithelial lymphocytes in the mucosae of SIVmac251- or simian-human immunodeficiency virus KU2-infected macaques.
Virology. 319: 190-200, 2004.
80)  Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, Princler GL, Derse D, Misteli T, Franchini G.
HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication.
Nat Med. 10: 197-201, 2004.
81)  Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J.
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.
Expert Rev Vaccines. 3: S75-88, 2004.
82)  Moniuszko M, Fry T, Tsai WP, Morre M, Assouline B, Cortez P, Lewis MG, Cairns S, Mackall C, Franchini G.
Recombinant interleukin-7 induces proliferation of naive macaque CD4+ and CD8+ T cells in vivo.
J. Virol. 78: 9740-9, 2004.
83)  Younis I, Khair L, Dundr M, Lairmore MD, Franchini G, Green PL.
Repression of human T-cell leukemia virus type 1 and type 2 replication by a viral mRNA-encoded posttranscriptional regulator.
J. Virol. 78: 11077-83, 2004.
84)  Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas ML, McChesney MB, McCullough R, Mhalu F, Salmon-Ceron D, Sekaly RP, van Rompay K, Verrier B, Wahren B, Weissenbacher M.
Support for the RV144 HIV vaccine trial.
Science. 305: 177-80; author reply 177-80, 2004.
85)  Price DA, West SM, Betts MR, Ruff LE, Brenchley JM, Ambrozak DR, Edghill-Smith Y, Kuroda MJ, Bogdan D, Kunstman K, Letvin NL, Franchini G, Wolinsky SM, Koup RA, Douek DC.
T cell receptor recognition motifs govern immune escape patterns in acute SIV infection.
Immunity. 21: 793-803, 2004.
86)  Nacsa J, Stanton J, Kunstman KJ, Tsai WP, Watkins DI, Wolinsky SM, Franchini G.
Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251.
Virology. 305: 210-8, 2003.
87)  Moniuszko M, Brown C, Pal R, Tryniszewska E, Tsai WP, Hirsch VM, Franchini G.
High frequency of virus-specific CD8+ T cells in the central nervous system of macaques chronically infected with simian immunodeficiency virus SIVmac251.
J. Virol. 77: 12346-51, 2003.
88)  Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH.
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Blood. 101: 4653-9, 2003.
89)  Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, Franchini G.
Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription.
J. Biol. Chem. 278: 12310-8, 2003.
90)  Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S, Hecht TT, Hill BJ, Komschlies K, Tomaszewski J, Franchini G, Mackall CL.
IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates.
Blood. 101: 2294-9, 2003.
91)  Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, Tryniszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G.
Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.
J Infect Dis. 188: 1181-91, 2003.
92)  Radaelli A, Nacsa J, Tsai WP, Edghill-Smith Y, Zanotto C, Elli V, Venzon D, Tryniszewska E, Markham P, Mazzara GP, Panicali D, De Giuli Morghen C, Franchini G.
Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251.
Virology. 312: 181-95, 2003.
93)  Franchini G, Nicot C, Johnson JM.
Seizing of T cells by human T-cell leukemia/lymphoma virus type 1.
Adv Cancer Res. 89: 69-132, 2003.
94)  Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA.
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.
Proc. Natl. Acad. Sci. U.S.A. 100: 9458-63, 2003.
95)  Franchini G, Fukumoto R, Fullen JR.
T-cell control by human T-cell leukemia/lymphoma virus type 1.
Int. J. Hematol. 78: 280-96, 2003.
96)  Hel Z, Johnson JM, Tryniszewska E, Tsai WP, Harrod R, Fullen J, Tartaglia J, Franchini G.
A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine.
Vaccine. 20: 3171-86, 2002.
97)  Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, VanCott TC, Hirsch V, Woodward R, Gibson A, Grace M, Dobratz E, Markham PD, Hel Z, Nacsa J, Klein M, Tartaglia J, Franchini G.
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
J. Virol. 76: 292-302, 2002.
98)  Stevceva L, Alvarez X, Lackner AA, Tryniszewska E, Kelsall B, Nacsa J, Tartaglia J, Strober W, Franchini G.
Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
J. Virol. 76: 11659-76, 2002.
99)  Stevceva L, Kelsall B, Nacsa J, Moniuszko M, Hel Z, Tryniszewska E, Franchini G.
Cervicovaginal lamina propria lymphocytes: phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to simian immunodeficiency virus SIVmac251.
J. Virol. 76: 9-18, 2002.
100)  Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, Felber BK, Tartaglia J, Pavlakis GN, Franchini G.
Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
J Immunol. 169: 4778-87, 2002.
101)  Hel Z, Tryniszewska E, Tsai WP, Johnson JM, Harrod R, Fullen J, Kalyanaraman VS, Altman JD, McNally J, Karpova T, Felber BK, Tartaglia J, Franchini G.
Design and in vivo immunogenicity of a polyvalent vaccine based on SIVmac regulatory genes.
DNA Cell Biol. 21: 619-26, 2002.
102)  Mothé BR, Horton H, Carter DK, Allen TM, Liebl ME, Skinner P, Vogel TU, Fuenger S, Vielhuber K, Rehrauer W, Wilson N, Franchini G, Altman JD, Haase A, Picker LJ, Allison DB, Watkins DI.
Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.
J. Virol. 76: 875-84, 2002.
103)  Hel Z, Nacsa J, Tsai WP, Thornton A, Giuliani L, Tartaglia J, Franchini G.
Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques.
Virology. 304: 125-34, 2002.
104)  Franchini G, Nacsa J, Hel Z, Tryniszewska E.
Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model.
Vaccine. 20 Suppl 4: A52-60, 2002.
105)  Santra S, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE, Lord CI, Pal R, Franchini G, Letvin NL.
Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys.
J. Immunol. 168: 1847-53, 2002.
106)  Johnson JM, Franchini G.
Retroviral proteins that target the major histocompatibility complex class I.
Virus Res. 88: 119-27, 2002.
107)  Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, Hel Z, Parks RW, Moniuszko M, Tartaglia J, Smith KA, Franchini G.
Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.
J Immunol. 169: 5347-57, 2002.
108)  Stevceva L, Tryniszewska E, Hel Z, Nacsa J, Kelsall B, Washington Parks R, Franchini G.
Differences in time of virus appearance in the blood and virus-specific immune responses in intravenous and intrarectal primary SIVmac251 infection of rhesus macaques; a pilot study.
BMC Infect. Dis. 1: 9, 2001.
109)  Johnson JM, Nicot C, Fullen J, Ciminale V, Casareto L, Mulloy JC, Jacobson S, Franchini G.
Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein.
J. Virol. 75: 6086-94, 2001.
110)  Nicot C, Mulloy JC, Ferrari MG, Johnson JM, Fu K, Fukumoto R, Trovato R, Fullen J, Leonard WJ, Franchini G.
HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells.
Blood. 98: 823-9, 2001.
111)  Nicot C, Mahieux R, Pise-Masison C, Brady J, Gessain A, Yamaoka S, Franchini G.
Human T-cell lymphotropic virus type 1 Tax represses c-Myb-dependent transcription through activation of the NF-kappaB pathway and modulation of coactivator usage.
Mol. Cell. Biol. 21: 7391-402, 2001.
112)  Ferrari MG, Rivadeneira ED, Jarrett R, Stevceva L, Takemoto S, Markham P, Franchini G.
HV(MNE), a novel lymphocryptovirus related to Epstein-Barr virus, induces lymphoma in New Zealand White rabbits.
Blood. 98: 2193-9, 2001.
113)  Kazanji M, Tartaglia J, Franchini G, de Thoisy B, Talarmin A, Contamin H, Gessain A, de Thé G.
Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).
J. Virol. 75: 5939-48, 2001.
114)  Hel Z, Nacsa J, Kelsall B, Tsai WP, Letvin N, Parks RW, Tryniszewska E, Picker L, Lewis MG, Edghill-Smith Y, Moniuszko M, Pal R, Stevceva L, Altman JD, Allen TM, Watkins D, Torres JV, Berzofsky JA, Belyakov IM, Strober W, Franchini G.
Impairment of Gag-specific CD8(+) T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques.
J. Virol. 75: 11483-95, 2001.
115)  Johnson JM, Harrod R, Franchini G.
Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1).
Int J Exp Pathol. 82: 135-47, 2001.
116)  Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, Watkins DI, Allen TM, Sette A, Altman J, Woodward R, Markham PD, Clements JD, Franchini G, Strober W, Berzofsky JA.
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.
Nat. Med. 7: 1320-6, 2001.
117)  Hel Z, Tsai WP, Thornton A, Nacsa J, Giuliani L, Tryniszewska E, Poudyal M, Venzon D, Wang X, Altman J, Watkins DI, Lu W, von Gegerfelt A, Felber BK, Tartaglia J, Pavlakis GN, Franchini G.
Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen.
J Immunol. 167: 7180-91, 2001.
118)  Nicot C, Mahieux R, Takemoto S, Franchini G.
Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples.
Blood. 96: 275-81, 2000.
119)  Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M.
Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
AIDS. 14: 2445-55, 2000.
120)  Trovato R, Cereseto A, Takemoto S, Gessain A, Watanabe T, Waldmann T, Franchini G.
Deletion of the p16INK4A gene in ex vivo acute adult T cell lymphoma/leukemia cells and methylation of the p16INK4A promoter in HTLV type I-infected T cell lines.
AIDS Res. Hum. Retroviruses. 16: 709-13, 2000.
121)  Nicot C, Mahieux R, Opavsky R, Cereseto A, Wolff L, Brady JN, Franchini G.
HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300.
Oncogene. 19: 2155-64, 2000.
122)  Kuroda MJ, Schmitz JE, Lekutis C, Nickerson CE, Lifton MA, Franchini G, Harouse JM, Cheng-Mayer C, Letvin NL.
Human immunodeficiency virus type 1 envelope epitope-specific CD4(+) T lymphocytes in simian/human immunodeficiency virus-infected and vaccinated rhesus monkeys detected using a peptide-major histocompatibility complex class II tetramer.
J. Virol. 74: 8751-6, 2000.
123)  Takemoto S, Trovato R, Cereseto A, Nicot C, Kislyakova T, Casareto L, Waldmann T, Torelli G, Franchini G.
p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells.
Blood. 95: 3939-44, 2000.
124)  Beer BE, Bailes E, Dapolito G, Campbell BJ, Goeken RM, Axthelm MK, Markham PD, Bernard J, Zagury D, Franchini G, Sharp PM, Hirsch VM.
Patterns of genomic sequence diversity among their simian immunodeficiency viruses suggest that L'Hoest monkeys (Cercopithecus lhoesti) are a natural lentivirus reservoir.
J. Virol. 74: 3892-8, 2000.
125)  Margolis L, Glushakova S, Chougnet C, Shearer G, Markham P, Robert-Guroff M, Benveniste R, Miller CJ, Cranage M, Hirsch V, Franchini G.
Replication of simian immunodeficiency virus (SIV) in ex vivo lymph nodes as a means to assess susceptibility of macaques in vivo.
Virology. 275: 391-7, 2000.
126)  Stevceva L, Abimiku AG, Franchini G.
Targeting the mucosa: genetically engineered vaccines and mucosal immune responses.
Genes Immun. 1: 308-15, 2000.
127)  Nicot C, Opavsky R, Mahieux R, Johnson JM, Brady JN, Wolff L, Franchini G.
Tax oncoprotein trans-represses endogenous B-myb promoter activity in human T cells.
AIDS Res. Hum. Retroviruses. 16: 1629-32, 2000.
128)  Dekaban GA, Peters AA, Mulloy JC, Johnson JM, Trovato R, Rivadeneira E, Franchini G.
The HTLV-I orfI protein is recognized by serum antibodies from naturally infected humans and experimentally infected rabbits.
Virology. 274: 86-93, 2000.
129)  Johnson JM, Mulloy JC, Ciminale V, Fullen J, Nicot C, Franchini G.
The MHC class I heavy chain is a common target of the small proteins encoded by the 3' end of HTLV type 1 and HTLV type 2.
AIDS Res. Hum. Retroviruses. 16: 1777-81, 2000.
130)  D'Agostino DM, Zotti L, Ferro T, Franchini G, Chieco-Bianchi L, Ciminale V.
The p13II protein of HTLV type 1: comparison with mitochondrial proteins coded by other human viruses.
AIDS Res. Hum. Retroviruses. 16: 1765-70, 2000.
131)  Hel Z, Venzon D, Poudyal M, Tsai WP, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman JD, Watkins D, Bischofberger N, Abimiku A, Markham P, Tartaglia J, Franchini G.
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques.
Nat Med. 6: 1140-6, 2000.
132)  Trovato R, Mulloy JC, Johnson JM, Takemoto S, de Oliveira MP, Franchini G.
A lysine-to-arginine change found in natural alleles of the human T-cell lymphotropic/leukemia virus type 1 p12(I) protein greatly influences its stability.
J. Virol. 73: 6460-7, 1999.
133)  Rivadeneira ED, Ferrari MG, Jarrett RF, Armstrong AA, Markham P, Birkebak T, Takemoto S, Johnson-Delaney C, Pecon-Slattery J, Clark EA, Franchini G.
A novel Epstein-Barr virus-like virus, HV(MNE), in a Macaca nemestrina with mycosis fungoides.
Blood. 94: 2090-101, 1999.
134)  Leno M, Carter L, Venzon DJ, Romano J, Markham PD, Limbach K, Tartaglia J, Paoletti E, Benson J, Franchini G, Robert-Guroff M.
CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy.
AIDS Res. Hum. Retroviruses. 15: 461-70, 1999.
135)  Ekholm D, Mulloy JC, Gao G, Degerman E, Franchini G, Manganiello VC.
Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes.
Biochem. Pharmacol. 58: 935-50, 1999.
136)  Cereseto A, Kislyakova T, Washington Parks R, Nicot C, Franchini G.
Differential response to genotoxic stress in immortalized or transformed human T-lymphotropic virus type I-infected T-cells.
J. Gen. Virol. 80 ( Pt 7): 1575-81, 1999.
137)  Slattery JP, Franchini G, Gessain A.
Genomic evolution, patterns of global dissemination, and interspecies transmission of human and simian T-cell leukemia/lymphotropic viruses.
Genome Res. 9: 525-40, 1999.
138)  Cereseto A, Washington Parks R, Rivadeneira E, Franchini G.
Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells.
Oncogene. 18: 2441-50, 1999.
139)  Ciminale V, Zotti L, D'Agostino DM, Ferro T, Casareto L, Franchini G, Bernardi P, Chieco-Bianchi L.
Mitochondrial targeting of the p13II protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I).
Oncogene. 18: 4505-14, 1999.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/3/2014.